633 related articles for article (PubMed ID: 32978971)
1. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage.
Amor S; Fernández Blanco L; Baker D
Clin Exp Immunol; 2020 Nov; 202(2):193-209. PubMed ID: 32978971
[TBL] [Abstract][Full Text] [Related]
2. The Science Underlying COVID-19: Implications for the Cardiovascular System.
Liu PP; Blet A; Smyth D; Li H
Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
[TBL] [Abstract][Full Text] [Related]
3. Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in an
Liang Y; Li H; Li J; Yang ZN; Li JL; Zheng HW; Chen YL; Shi HJ; Guo L; Liu LD
Zool Res; 2020 Nov; 41(6):621-631. PubMed ID: 33045777
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
6. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
7. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
8. Lessons from dermatology about inflammatory responses in Covid-19.
Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function.
Winkler ES; Bailey AL; Kafai NM; Nair S; McCune BT; Yu J; Fox JM; Chen RE; Earnest JT; Keeler SP; Ritter JH; Kang LI; Dort S; Robichaud A; Head R; Holtzman MJ; Diamond MS
Nat Immunol; 2020 Nov; 21(11):1327-1335. PubMed ID: 32839612
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2.
Breiman A; Ruvën-Clouet N; Le Pendu J
PLoS Pathog; 2020 May; 16(5):e1008556. PubMed ID: 32437478
[No Abstract] [Full Text] [Related]
11. SARS-CoV-2 and interferon blockade.
Diamond B; Volpe BT; VanPatten S; Al Abed Y
Mol Med; 2020 Nov; 26(1):103. PubMed ID: 33167852
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
Meini S; Zanichelli A; Sbrojavacca R; Iuri F; Roberts AT; Suffritti C; Tascini C
Front Immunol; 2020; 11():2014. PubMed ID: 32849666
[TBL] [Abstract][Full Text] [Related]
14. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
16. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 as a Factor to Disbalance the Renin-Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production.
Franco R; Rivas-Santisteban R; Serrano-Marín J; Rodríguez-Pérez AI; Labandeira-García JL; Navarro G
J Immunol; 2020 Sep; 205(5):1198-1206. PubMed ID: 32680957
[TBL] [Abstract][Full Text] [Related]
18. Activation and evasion of type I interferon responses by SARS-CoV-2.
Lei X; Dong X; Ma R; Wang W; Xiao X; Tian Z; Wang C; Wang Y; Li L; Ren L; Guo F; Zhao Z; Zhou Z; Xiang Z; Wang J
Nat Commun; 2020 Jul; 11(1):3810. PubMed ID: 32733001
[TBL] [Abstract][Full Text] [Related]
19. Why is SARS-CoV-2 infection milder among children?
Palmeira P; Barbuto JAM; Silva CAA; Carneiro-Sampaio M
Clinics (Sao Paulo); 2020; 75():e1947. PubMed ID: 32428111
[No Abstract] [Full Text] [Related]
20. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
